197 related articles for article (PubMed ID: 25956340)
1. The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Bae DS; Kim BG
Eur J Obstet Gynecol Reprod Biol; 2015 Jul; 190():26-30. PubMed ID: 25956340
[TBL] [Abstract][Full Text] [Related]
2. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix.
Denehy TR; Gregori CA; Breen JL
Obstet Gynecol; 1997 Jul; 90(1):1-6. PubMed ID: 9207802
[TBL] [Abstract][Full Text] [Related]
3. The suitable treatment for adenocarcinoma in situ of uterine cervix: a report of four cases.
Liu YC; Chen RJ; Chang DY; Huang SC; Chow SN
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Oct; 58(4):294-8. PubMed ID: 8994337
[TBL] [Abstract][Full Text] [Related]
4. Adenocarcinoma in situ of the uterine cervix.
Muntz HG; Bell DA; Lage JM; Goff BA; Feldman S; Rice LW
Obstet Gynecol; 1992 Dec; 80(6):935-9. PubMed ID: 1448263
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinoma in situ coexisting with carcinoma in situ of the cervix during pregnancy.
Nagaishi M; Fujiwaki R; Hata K; Makihara K; Yamane Y; Miyazaki K
Arch Gynecol Obstet; 2004 Sep; 270(2):116-8. PubMed ID: 15449069
[TBL] [Abstract][Full Text] [Related]
6. Risk for residual adenocarcinoma in situ or cervical adenocarcinoma in women undergoing loop electrosurgical excision procedure/conization for adenocarcinoma in situ.
DeSimone CP; Day ME; Dietrich CS; Tovar MM; Modesitt SC
J Reprod Med; 2011; 56(9-10):376-80. PubMed ID: 22010519
[TBL] [Abstract][Full Text] [Related]
7. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix.
Poynor EA; Barakat RR; Hoskins WJ
Gynecol Oncol; 1995 May; 57(2):158-64. PubMed ID: 7729727
[TBL] [Abstract][Full Text] [Related]
8. Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins.
Munro A; Codde J; Spilsbury K; Stewart CJ; Steel N; Leung Y; Tan J; Salfinger SG; Mohan GR; Semmens JB; Cohen PA
Acta Obstet Gynecol Scand; 2017 Apr; 96(4):432-437. PubMed ID: 28181670
[TBL] [Abstract][Full Text] [Related]
9. Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease.
Im DD; Duska LR; Rosenshein NB
Gynecol Oncol; 1995 Nov; 59(2):179-82. PubMed ID: 7590468
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.
Srisomboon J; Kietpeerakool C; Suprasert P; Siriaunkgul S; Khunamornpong S; Prompittayarat W
Asian Pac J Cancer Prev; 2007; 8(2):225-8. PubMed ID: 17696736
[TBL] [Abstract][Full Text] [Related]
11. Severe cervical glandular cell lesions with coexisting squamous cell lesions.
van Aspert-van Erp AJ; Smedts FM; Vooijs GP
Cancer; 2004 Aug; 102(4):218-27. PubMed ID: 15368313
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcinoma in situ of the uterine cervix: management and outcome.
Widrich T; Kennedy AW; Myers TM; Hart WR; Wirth S
Gynecol Oncol; 1996 Jun; 61(3):304-8. PubMed ID: 8641606
[TBL] [Abstract][Full Text] [Related]
13. [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases].
Dedecker F; Graesslin O; Bonneau S; Quéreux C
Gynecol Obstet Fertil; 2008 Jun; 36(6):616-22. PubMed ID: 18539502
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinoma in situ of the cervix: management and outcome.
Azodi M; Chambers SK; Rutherford TJ; Kohorn EI; Schwartz PE; Chambers JT
Gynecol Oncol; 1999 Jun; 73(3):348-53. PubMed ID: 10366458
[TBL] [Abstract][Full Text] [Related]
15. Conservative management of adenocarcinoma in situ of the cervix.
Shin CH; Schorge JO; Lee KR; Sheets EE
Gynecol Oncol; 2000 Oct; 79(1):6-10. PubMed ID: 11006022
[TBL] [Abstract][Full Text] [Related]
16. Cervical adenocarcinoma in situ: the predictive value of conization margin status.
Young JL; Jazaeri AA; Lachance JA; Stoler MH; Irvin WP; Rice LW; Andersen WA; Modesitt SC
Am J Obstet Gynecol; 2007 Aug; 197(2):195.e1-7; discussion 195.e7-8. PubMed ID: 17689647
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
Costa S; Negri G; Sideri M; Santini D; Martinelli G; Venturoli S; Pelusi C; Syrjanen S; Syrjanen K; Pelusi G
Gynecol Oncol; 2007 Jul; 106(1):170-6. PubMed ID: 17481701
[TBL] [Abstract][Full Text] [Related]
18. Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial.
Schorge JO; Lea JS; Ashfaq R
J Reprod Med; 2003 Oct; 48(10):751-5. PubMed ID: 14619639
[TBL] [Abstract][Full Text] [Related]
19. [Endocervical adenocarcinoma in situ. A histological entity to know].
Fignon A; Mayelo V; Wurst C; Magnin G; Tariel D; Descamps P; Renjard L; Body G; Lansac J
J Gynecol Obstet Biol Reprod (Paris); 1995; 24(4):369-73. PubMed ID: 7650312
[TBL] [Abstract][Full Text] [Related]
20. Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix?
Akiba Y; Kubushiro K; Fukuchi T; Fujii T; Tsukazaki K; Mukai M; Nozawa S
J Obstet Gynaecol Res; 2005 Jun; 31(3):252-6. PubMed ID: 15916663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
